Full title: Effects of maternal and paternal smoking on offspring cardiometabolic risk factors in

adulthood: a multi-method intergenerational Mendelian randomization study

Short title: Parental smoking and adult offspring cardiometabolic risk

Authors: Grace M. Power[1,2,3]*[¶], Tom A. Bond[1,2,3,4,5][¶], Laxmi Bhatta[3,6], Bjørn Olav Åsvold[6,7,8], Ben

Brumpton[6,7,9], Gibran Hemani[1,2], Deborah A. Lawlor[1,2], Geng Wang[3], Nicole Warrington[3,4],

David M. Evans[1,3,4&], Gunn-Helen Moen[3,4,6,10&], George Davey Smith[1,2,11&]

* Corresponding author: Grace M. Power (grace.power@bristol.ac.uk).

[¶] These authors contributed equally to this work (joint first authors).

[&] These authors also contributed equally to this work (joint senior authors).

Affiliations.

[1]*MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.*

[2]*Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.*

[3]*Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.*

[4]*Frazer Institute, University of Queensland, Woolloongabba, Australia.*

[5]*Department of Epidemiology and Biostatistics, Imperial College London, London, UK.*

[6]*HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and*

Nursing, NTNU Norwegian University of Science and Technology, Trondheim, Norway.

[7]*HUNT Research Centre, Department of Public Health and Nursing, NTNU Norwegian University*

of Science and Technology, Levanger, Norway.

[8]*Department of Endocrinology, Clinic of Medicine, St. Olavs Hospital, Trondheim University*

Hospital, Trondheim 7030, Norway.

[9]*Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.*

[10]*Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.*

[11]*NIHR Bristol Biomedical Research Centre Bristol, University Hospitals Bristol and Weston NHS*

Foundation Trust, University of Bristol, Bristol, UK.

Abstract.

Parental smoking has been linked to several adverse offspring cardiometabolic outcomes;

however, evidence is conflicting regarding the causal and long-term nature of these

associations. We investigated the effects of maternal and paternal smoking, capturing

exposure before, during, and after pregnancy, on eleven offspring cardiometabolic risk factors

related to body composition, blood pressure, glucose, and lipid levels in adulthood. We applied

a multi-method intergenerational Mendelian randomization (MR) framework, combining two-

sample MR (outcome GWAS n = up to 564,160) and one-sample MR using genetic risk score

(GRS) analyses (n = up to 17,484 genotyped mother, father, offspring trios with offspring

cardiometabolic risk factors) from the Norwegian HUNT cohort and British UK Biobank and

ALSPAC cohorts. Smoking behaviour was instrumented using genome-wide significant variants

for smoking initiation and heaviness from large genome-wide association studies (2019 and

2022), with additional analyses of the *CHRNA5* variant rs16969968.

Using the two-sample MR approach, we found that an average change in adult offspring waist-

hip-ratio (WHR) per one standard deviation (SD) increase in maternal cigarettes smoked per

day of 0.25 SD (95% CI: 0.13, 0.38; 2019 GWAS), 0.19 SD (95% CI: 0.08, 0.31; 2022 GWAS) and

0.27 SD (95% CI: 0.07, 0.47; *CHRNA5* rs16969968). We also found tentative evidence of

comparable effects on offspring body mass index and C-reactive protein. One-sample MR

analyses using *CHRNA5* rs16969968, restricted to maternal ever-smokers, provided supporting

evidence for a causal effect of maternal smoking heaviness on offspring WHR. We found little

evidence that maternal smoking initiation affected WHR, and little evidence that maternal

smoking heaviness affected the remaining cardiometabolic risk factors; paternal smoking

showed no clear effect on any outcome. Results from sensitivity analyses were consistent with

these main findings.

Our finding of higher central adiposity in adult offspring of mothers with a propensity to smoke

more heavily provides further incentive for prospective mothers to quit or reduce smoking

heaviness before, during, and after pregnancy. Triangulating these findings using alternative

methods would be valuable.

Introduction.

Cardiovascular diseases (CVDs) are the most common cause of mortality worldwide (1). The Developmental Origins of Health and Disease (DOHaD) framework postulates that the development of adult cardiovascular disease is influenced by the environment in the preconception, fertilization, embryonic, fetal, and neonatal periods (2, 3). Environmental insults in early life are hypothesised to impede development, resulting in the permanent 'programming' of endocrine and metabolic function (4, 5), subsequently heightening susceptibility to cardiometabolic disease in adulthood (2, 6-9).

Smoking by mothers during pregnancy is a well-established modifiable risk factor for several adverse perinatal health outcomes (10, 11). Whilst attention has largely focused on the effects of maternal smoking on conception, pregnancy, fetal and child health, there have been concerns that perinatal exposure to smoking may play an important role in increased risk of cardiometabolic disorders in offspring in their later life (11, 12). Previous conventional epidemiological analyses have shown that parental smoking is associated with increased incidence of later life obesity and related comorbidities. For example, a meta-analysis comprising 19 multivariable regression studies (n=24,201 to 308,981) found that maternal prenatal smoking was associated with higher risks of overweight, obesity, and gestational diabetes mellitus in adult offspring, but not type 2 diabetes, hypertension, waist circumference, or total cholesterol (13). In addition, an individual patient data meta-analysis which included 26 studies of mother-child-pairs (n=238,340) indicated a positive linear dose-response relationship between the number of cigarettes smoked by mothers during pregnancy and offspring overweight in childhood and adolescence for up to 15 cigarettes per day (14). An association has also been identified between paternal smoking during preadolescence and increased BMI, fat mass, and waist circumference in male offspring, with no corresponding effect observed in female offspring (15). However, a larger study conducted in the Trøndelag Health Study (HUNT), designed to reproduce these earlier findings, found little evidence that exposure to parental smoke in preadolescence was associated with offspring BMI at a mean age of 29.1 years (16). Epigenetic studies have suggested that maternal and/or paternal smoking may affect DNA methylation in the offspring, including robust evidence for persistent methylation changes following maternal smoking in pregnancy, providing a plausible mechanism by which parental smoking could increase offspring obesity risk (17, 18).

The evidence for a causal effect of parental smoking on offspring cardiometabolic risk is

contradictory. A proxy gene-by-environment Mendelian randomization (MR) study found little

evidence for a causal effect of maternal smoking on 12 long-term offspring outcomes, including

BMI and blood pressure, although the authors acknowledged a lack of power to detect such

effects (19). In addition, studies employing a sibling comparison design, which contrasts

siblings with discordant exposure to maternal smoking during pregnancy (with the aim of

controlling for confounders that are shared by siblings), concluded that the observed

associations between maternal smoking during pregnancy and offspring obesity were more

likely to be confounded by shared familial characteristics than reflect a causal intrauterine

mechanism (20, 21). Earlier paternal negative control studies suggested that maternal smoking

in pregnancy showed larger associations with childhood overweight and obesity than paternal

smoking in mutually adjusted models, which was interpreted as being more consistent with a

causal intrauterine effect (22). This study design assumes that if a causal intrauterine effect of

the maternal exposure on the offspring is present, the association of the maternal exposure

with the outcome should be larger than the association of the equivalent paternal exposure

(23). However, evidence from an individual participant data meta-analysis of 229,158 families

shows that maternal and paternal smoking have similar associations with childhood

overweight, a pattern more consistent with shared familial confounding than with a specific

intrauterine effect (24).

Plausible explanations for the identification of an association between maternal or paternal

smoking and cardiometabolic outcomes in adult offspring include: (i) consequences from

noxious chemicals found in cigarette smoke impacting the oocyte or sperm, (ii) adverse

intrauterine effects from associated chemical insults, (iii) postnatal exposure to parental

smoking for the offspring, or (iv) potential confounding bias. In conventional epidemiological

settings, biases induced by confounding pose challenges when inferring causality. Associations

identified could be due to environmental confounding or to shared genetic effects (25).

Mendelian randomization (MR) is a technique that, provided specific assumptions are met,

exploits the random distribution of genetic variants from parents to offspring, independent of

the influence of other traits. This reduces susceptibility to confounding factors, including

confounding by undiagnosed existing disease (reverse causation) (26, 27). Recent

developments in intergenerational MR methodology (28) enable indirect estimation of the

effects of parental exposures on offspring adulthood outcomes by accounting for the direct

fetal genotype contribution (6).

We aimed to use intergenerational MR to test the hypothesis that maternal and paternal

smoking – before, during, or after pregnancy – cause a more adverse offspring cardiometabolic

risk factor profile in adulthood.

Methods.

This study adheres to the Strengthening The Reporting of Observational Studies in

Epidemiology Using Mendelian Randomisation (STROBE-MR) guidelines *(29, 30)*

(Supplementary Material 1).

<u>Data sources and instruments</u>

Inclusion criteria and participating cohorts

We analysed three large population-based prospective cohorts that had genome-wide SNP

data available in mothers, fathers and offspring and cardiometabolic risk factors measured in

adult offspring: the Trøndelag Health Study (HUNT), the UK Biobank (UKB), and the Avon

Longitudinal Study of Parents and Children (ALSPAC). The selection of study participants for

our main two-sample MR analysis is presented in Figure 1. Study participant selection for one-

sample MR is presented in Figure S1.

HUNT. HUNT is a cohort study of the adult population in Trøndelag County, Norway, and

comprises ~230,000 individuals aged ≥20 years (31, 32). Individuals were recruited in four

surveys from 1984–2019, of which the HUNT2 and HUNT3 surveys were included in the

present study. Invitee participation rates were 69% and 54%, respectively. Data on perinatal

outcomes are available via linkage to the Medical Birth Registry of Norway (MBRN) (33) for

individuals born after 1967. A total of 69,716 European ancestry offspring were available in

HUNT, with genotype data available, of which 26,040 had maternal genotype data available

and 19,784 had psaternal genotype data available (6, 34, 35). Parent-offspring pairs and trios

were identified using kinship analysis implemented in the KING software package (36).

UKB. UKB is a cohort of 503,317 adult volunteers, recruited from across the UK aged 40–69

years between 2006 and 2010 (37). Parent-offspring pairs and trios were identified using

kinship analysis implemented in the KING software package (36).

ALSPAC. ALSPAC is a birth cohort which enrolled 14,541 pregnant women living in Avon,

England with expected dates of delivery between April 1, 1991, and December 31, 1992 (the

estimated recruitment rate of those eligible was 80%) (38, 39). Further enrolments after 1998

resulted in a baseline sample of 14,901 children alive at one year of age. We used data

collected during pregnancy/birth and the 24-year follow up. Some study data were collected

and managed using Research Electronic Data Capture (REDCap) electronic data capture tools

hosted at the University of Bristol (40). Please note that the study website contains details of

all the data that is available through a fully searchable data dictionary and variable search tool:

http://www.bristol.ac.uk/alspac/researchers/our-data/. Parent-offspring pairs and trios were

identified by matching on study ID variables.

Informed consent was obtained from all participants and ethical approval was obtained from

the Regional Committee for Medical and Health Research Ethics, Central Norway (REK Central

application number 2018/2488) (HUNT), the North West Multi-centre Research Ethics

Committee (MREC) (ref 11/NW/0382) (UKB), and the ALSPAC Ethics and Law Committee and

the Local Research Ethics Committees (ALSPAC).

Offspring cardiometabolic risk factors and birthweight

Standard protocols were used to assess the eleven offspring cardiometabolic outcomes in

adulthood (body mass index (BMI), waist-hip-ratio (WHR), systolic (SBP) and diastolic (DBP)

blood pressure, blood glucose, glycated haemoglobin (HbA1c), total cholesterol, high density

lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides and

high sensitivity C-reactive protein (CRP)) (41, 42). For one-sample MR analyses, CRP was only

available in ALSPAC and UKB and HbA1c was only available in UKB. Blood pressure and lipid

measurements were corrected for antihypertensive and lipid lowering medication use as

described previously (41, 42). Briefly, blood pressure values for participants in HUNT and UKB

who reported taking antihypertensive medication were corrected by adding 15 mmHg and 10

mmHg to the raw SBP and DBP values respectively. Lipid values were corrected for participants

reporting taking lipid lowering medication in UKB by dividing the raw LDL cholesterol values by

0.7 and the raw total cholesterol and triglyceride values by 0.8 (41, 42). Biochemical values

were measured in fasting blood samples in ALSPAC and non-fasting in HUNT and UKB. Offspring

birthweight was employed as a positive control outcome in this analysis. A priori, we expected

to see a negative causal effect of smoking during pregnancy on birthweight (43-45).

Birthweight was extracted from the Medical Birth Registry of Norway (MBRN) in HUNT,

measured by trained research assistants or abstracted from the birth record/notification in

ALSPAC, and retrospectively self-reported at recruitment in UKB. CRP was strongly right

skewed, therefore was natural log transformed prior to GWAS.

Genotyping, quality control and imputation in each cohort

Genotyping, quality control and imputation in each cohort are described in detail in the Supplementary Material 2 and elsewhere (34, 46-48). To summarise, participants were genotyped using genome-wide arrays, followed by imputation of genome-wide variants. HUNT participants were imputed using a customised Haplotype Reference Consortium (HRC) panel including 2,201 Norwegian whole genome sequences. ALSPAC mothers and offspring were imputed to the HRC panel (34, 47), and ALSPAC fathers to the 1000 Genomes phase 1 panel (48). UKB participants were imputed to a merged HRC/UK10K panel (46). Imputed variants with minor allele frequency (MAF) >1% and imputation accuracy score >0.8 were used for genome-wide association study (GWAS) analyses.

Parental smoking exposures

We explored effects of maternal and paternal smoking initiation (by using genetic variants associated with self-reported ever versus never smokers), intensity of smoking (by using genetic variants associated with self-reported number of cigarettes per day the rs16969968 genetic variant in the *CHRNA5* gene shown to act primarily via smoking heaviness (49, 50)). Thus, the measures we used aim to capture whether:

(i)   current smoking compared to never smoking causes an effect on the outcomes of interest, and

(ii)   the intensity of smoking on the outcomes of interest suggests a dose-response relationship.

This study utilised external genome-wide association studies (GWASs) carried out by the GWAS and Sequencing Consortium of Alcohol and Nicotine use (GSCAN) in 2019 and 2022 (Table S1) (51, 52). We use both 2019 and 2022 GWAS. Larger GWAS typically identify variants with smaller effect sizes, that may be more prone to pleiotropy if the primary phenotype is imprecisely defined. Consequently, the smaller 2019 GWAS may yield estimates that are less affected by pleiotropic bias. In addition, *CHRNA5* (which is a region containing the strongest signal for smoking heaviness) (49, 50) was investigated using rs16969968 as a single instrumental variable, sourced from the above 2022 GWAS of cigarettes per day (52). In addition, there is weak association of this variant with never and ever smoking, thus allowing stratification by these groups without introducing substantial collider bias (53). The GWAS

selected were conducted on participants of European ancestry to mitigate bias by population

stratification.

<u>Statistical analysis</u>

When genetic variants are used as instrumental variables in MR, the assumptions of

instrumental variables must be met, i.e., the genetic variants must (i) be strongly associated

with the exposure of interest and relevant to the population studied, here pregnant women

("relevance"), (ii) not share common causes with the outcome ("independence"), and (iii) not

affect the outcome other than through the exposure ("exclusion-restriction") (54).

To block the path from parental genotype through offspring genotype to the offspring outcome

in an intergenerational context (which would be a violation of the "exclusion restriction"

assumption), MR is robust if (i) summary outcome associations are extracted from adjusted

GWAS (parental genotype adjusted for offspring genotype and if relevant, the other parent's

genotype) in a two-sample setting, or (ii) the association between maternal or paternal

unweighted GRS and offspring outcomes is adjusted for offspring genotype (and if relevant,

other parent GRS), in a one-sample setting (6, 28, 55, 56). There are other valid ways to conduct

intergenerational one-sample MR (e.g. maternal non-transmitted alleles) (57), which will not

be used in this current study.

Summary level two-sample Mendelian randomisation

For the main analysis, we conducted two-sample intergenerational MR using previously

derived GWAS summary statistics for each cardiometabolic risk factor (combined n for

maternal, paternal and offspring GWAS = up to 564,160), which employed maternal and

paternal genotype, and adjusted for the offspring's genotype (41, 42). These were generated

using a weighted linear modelling (WLM) approach, implemented in the DONUTS R package,

accounting for the correlation between the parental genotypes (58). The WLM estimated the

adjusted genetic effects (i.e. the mutually adjusted coefficients for maternal, paternal and

offspring genotype, fitted jointly in the same model) as linear combinations of the unadjusted

genetic effects (i.e. the coefficients for maternal, paternal and offspring genotype fitted in

separate, partially overlapping samples) (55, 59, 60). We use the shorthand "unadjusted" to

refer specifically to models that are unadjusted for parental/offspring genotype, as opposed to

the other covariates, inclufing offspring age, sex, and genetic principal components, which

were included in all models. We found that MR estimates changed very little when using genetic effects from a "duos" WLM (that only adjusted for offspring genotype) compared with estimates from a "trios" WLM (that adjusted for offspring genotype and the other parent's genotype). Since the duos WLM yields smaller standard errors, we present the duos results as our primary analysis (trios results are presented in the supplementary information). GWASs were carried out on all outcomes using mother, father, and offspring genotypes. We assume that imputation quality is the same across maternal, paternal and offspring GWAS. Methods are described in detail elsewhere (41, 42). In brief, offspring outcomes were regressed separately on maternal, paternal or offspring imputed genotype dosages, adjusting for offspring sex, age at outcome measurement (including linear, quadratic and sex interaction effects, for all outcomes except birthweight), technical covariates and the top 20 genetic principal components (calculated from maternal, paternal or offspring genotypes respectively) to adjust for population stratification. A linear mixed model using the fastGWA method (61) was used to account for cryptic relatedness. Parent-offspring pairs of European ancestry, for whom parental genotype and offspring phenotype data were available, were used. These analyses were conducted with HUNT, UKB, and ALSPAC cohorts independently and then meta-analysed using a fixed effects model implemented in METAL version 2011-03-25 (62). Standard quality control (QC) procedures were carried out including calculating the Linkage Disequilibrium Score Regression (LDSC) intercept and attenuation ratio.

To estimate the causal maternal (Figure 2A) and paternal (Figure 2B) effects of smoking initiation and intensity on offspring outcomes we first used two-sample intergenerational MR, with the SNP-exposure estimates from the GSCAN GWAS and the SNP-outcome estimates from the adjusted maternal/paternal/offspring GWAS. We computed the inverse variance weighted (IVW) estimate which takes a weighted mean of the variant-specific causal estimates using inverse variance weights (63). In IVW analyses, the regression slope (ratio) is forced through a zero intercept. This assumes balanced horizontal pleiotropy. We additionally ran sensitivity analyses using MR-Egger, weighted median, and weighted mode methods (64-66). MR-Egger evaluates the potential presence of pleiotropic effects by allowing for a non-zero intercept in the regression of the variant-outcome estimates on variant-exposure estimates (64). It provides an unbiased estimate of the causal effect even in the presence of horizontal pleiotropy assuming that the INstrument Strength Independent of Direct Effect (InSIDE) assumption holds (67). The weighted median method provides an alternative estimate of the

causal effect by considering the weighted median rather than the weighted mean of the

instrumental variable estimates (65). We checked for evidence of horizontal pleiotropy via

Cochran's Q test for heterogeneity, and by testing whether the MR Egger intercept differed

from zero. There is evidence that genetic variants associated with smoking also influence body

composition, suggesting potential shared genetic pathways between smoking behaviours and

adiposity (68, 69). Smoking-associated genetic variants are also correlated with socioeconomic

position, commonly indexed by educational attainment, indicating that these variants may

capture both behavioural and socioeconomic influences (52, 70, 71). To account for these

overlapping genetic relationships, we applied multivariable MR (MVMR) in our two-sample

analyses to estimate the effect of smoking initiation and smoking intensity on WHR, conditional

on educational attainment and BMI. By modelling these exposures jointly, MVMR provides

smoking-WHR estimates that account for these shared genetic pathways, under the

multivariable IV assumptions (72, 73). Instrument strength in the multivariable MVMR models

was evaluated using conditional F-statistics, which account for the inclusion of multiple,

potentially correlated exposures. These analyses were performed using the *TwoSampleMR* R

package (58).

Results subsequently underwent adjustment for multiple testing using Bonferroni correction

for 12 outcomes (corrected significance level p=0.004) to protect against Type 1 error (74).

Details of the input parameters are presented in Table S2.

Individual-level one-sample MR using GRS analysis

In one-sample MR, we explored effects of maternal and paternal intensity of smoking using

instruments identified in the GWAS described previously (51, 52). These one-sample analyses

represent reduced form associations, where offspring outcomes are regressed directly on

parental genetic scores without scaling by the genetic association with smoking exposure.

Accordingly, offspring outcomes were regressed separately on maternal, paternal, or offspring

genetic instruments, assuming an additive genetic model. Results therefore reflect the overall

genetic-outcome association, not the causal effect per unit change in the smoking exposure.

Unweighted genetic scores were constructed by summing smoking-raising alleles (Table S3).

We additionally ran these analyses using just the variant rs16969968 in *CHRNA5*. We examined

the association between the parental GRS of interest and offspring outcomes, adjusting for the

offspring's genetic score (and the other parent's GRS) calculated from the same smoking

heaviness-associated SNPs. These analyses were conducted in up to 17,484 mother-father-

offspring trios from HUNT, UKB and ALSPAC.

We constructed an unweighted GRS since regression coefficients obtained in the smoking

GWAS's might not accurately reflect effect sizes during pregnancy (75, 76). We fitted a linear

mixed model implemented in the GCTA software package (77) using a genetic relatedness

matrix (GRM) constructed from the offspring genotypes to account for relatedness and

population stratification. Known smoking-associated SNPs and any SNPs within ±1 Mb of these

loci (to account for linkage disequilibrium) were excluded from GRM construction (6). SNPs

included in GRSs were selected from GWAS meta-analyses as genome-wide significant (P < 5 ×

10^{-8}) and conditionally independent, based on LD clumping or fine-mapping procedures

described by the original studies (51, 52). All analyses were adjusted for offspring age at

measurement and sex. The GRM mitigated the need to adjust for PCs. Parent-offspring pairs

of European ancestry, for whom parental genotype and offspring phenotype data were

available, were used. We implemented a complete-case approach, excluding individuals with

missing values from the analysis. These analyses were conducted in HUNT, UKB and ALSPAC

and then meta-analysed. A fixed-effects meta-analysis of regression coefficients from the three

cohorts was conducted using Stata version 16 (78).

Stratified analysis

If our genetic instruments for smoking heaviness (including rs16969968 in the *CHRNA5* gene)

are valid, we would expect these variants to only indicate a causal effect when the

mother/father is a smoker. If a causal effect is detected in parental never-smokers, this implies

that the *CHRNA5* gene is influencing the offspring outcome via mechanisms other than

smoking heaviness (i.e. horizontal pleiotropy). We therefore repeated the *CHRNA5* gene MR

analyses, stratifying the sample to parental ever-smokers and never-smokers (49). For two

sample analyses we only had a sufficiently large sample to run stratified analyses for

birthweight (because the WLM relies on LD score regression (79), which has stringent sample

size requirements), whereas we ran stratified one-sample analysis for adult outcomes too.

Results.

Summary level two-sample Mendelian randomisation

The GWAS meta-analyses used for the SNP-outcome association in the two-sample MR included between 14,481 (for HbA1c with paternal genotype) and 511,253 (for DBP with offspring genotype) participants (Table S4) (80, 81).

We found strong evidence of an average change in adult offspring WHR per one standard deviation (SD) increase in maternal cigarettes smoked per day of 0.25 SD (95% CI: 0.13, 0.38) using GWAS carried out in 2019, 0.19 SD (95% CI: 0.08, 0.31) using the GWAS carried out in 2022, and 0.27 SD (95% CI: 0.07, 0.47) using *CHRNA5* rs16969968 (Figure 3A, Table S5). The estimates presented here all derive from unstratified analyses; stratified analyses are presented later. There was weaker evidence that increased maternal smoking heaviness had a causal effect on higher BMI (average change in SD of BMI in adult offspring per maternal cigarettes smoked per day of 0.23 SD (95% CI: 0.07, 0.39) using GWAS carried out in 2019, 0.14 SD (95% CI: 0.00, 0.29) using GWAS carried out in 2022 and 0.11 SD (95% CI: -0.13, 0.35) using *CHRNA5* rs16969968) and CRP (average change in SD of CRP in adult offspring 1SD greater maternal cigarettes smoked per day of 0.24 SD (95% CI: 0.08, 0.40) using GWAS carried out in 2019, 0.20 SD (95% CI: 0.04, 0.36) using GWAS carried out in 2022, and 0.25 SD (95% CI: 0.01, 0.49) using *CHRNA5* rs16969968). Corresponding paternal effect estimates are presented in Table S6. In the analyses using the trios WLM for the outcome GWAS (in which the parental genetic effects were adjusted for the other parent's genotype as well as the offspring's genotype), results were similar, although the confidence intervals were wider due to the lower statistical power of the trios WLM versus the duos WLM (Figure S2).

Point estimates from the two-sample weighted median, weighted mode and MR-Egger methods were similar to IVW estimates and evidence remained robust for the maternal effect for smoking heaviness on offspring WHR in later life (Table S5). In addition, Cochran's Q test provided little evidence for between-SNP heterogeneity, and there was not strong evidence that the MR Egger intercept differed from zero (Table S7). This suggests little evidence that horizontal pleiotropy is driving these results. After correcting for multiple testing using a Bonferroni test, evidence of an effect remained for maternal smoking heaviness on increased WHR and BMI only (using p=0.004). Findings for adult offspring outcomes using the unadjusted

GWAS sensitivity analyses are presented in Table S8 for maternal exposures and Table S9 for

paternal exposures. MVMR analyses indicated that there remained strong evidence for the

effect of maternal smoking heaviness on WHR in offspring in later life after accounting for BMI

as well as educational attainment (Table S10). There was little evidence of an effect of either

educational attainment or BMI on WHR in offspring after adjustment for any maternal smoking

indicator. Comparison of the conditional F-statistics showed that the instruments for BMI and

educational attainment were substantially stronger than those for the smoking exposures

(Table S10). The strength of the BMI and educational attainment instruments was largely

preserved when conditioned on smoking, indicating that these estimates were not affected by

SNP non-overlap. In contrast, conditioning led to considerable weakening of the smoking

instruments, consistent with the shared genetic architecture between smoking behaviour and

BMI. Accordingly, estimates for smoking heaviness should be interpreted with some caution;

however, the persistence of an association with offspring WHR after adjustment for BMI

suggests that this effect is not solely attributable to shared genetic pathways and may in fact

be attenuated by weak-instrument bias.

Individual-level one-sample MR using GRS analysis

The individual-level one-sample GRS analysis comprised between 16,942 and 17,484 mother-

father-offspring trios (Table 1 and Table S11). These one-sample analyses represent reduced

form associations between parental genetic scores and offspring outcomes. One-sample MR

in the total population indicated that higher genetically predicted maternal smoking heaviness

(using rs16969968 in the *CHRNA5* SNP) had a positive effect on WHR, TC, and LDL-cholesterol

in offspring in later life (Figure 4A, Table S12). There was no evidence of paternal smoking

effects (Figure 4B, Table S13). Cohort-specific results are presented in Tables S14-S16. Effect

estimates obtained using the unweighted smoking GRS were smaller than those from

rs16969968 in *CHRNA5*, consistent with differences in instrument scale: a single *CHRNA5* allele

has a larger established effect on smoking intensity than a one-allele change in the unweighted

multi-locus score. Consequently, the unweighted GRS yields more diluted reduced-form

associations.

Stratified analysis

For GWAS of birthweight stratified by parental smoking status, analysis comprised between
10,719 and 136,933 participants in maternal ever smokers, 8,094 and 104,002 participants in
maternal never smokers, 9,425 and 27,726 participants in paternal ever smokers and 5,367
and 18,718 participants in paternal never smokers (Table S17). In analyses employing the
unadjusted GWAS (i.e. using genetic effects that were not adjusted for the offspring's or other
parent's genotype), in the unstratified sample (including parental never and ever smokers) we
found suggestive evidence that maternal and paternal smoking initiation caused lower
birthweight (Figure 5, Table S18). We also found some weak evidence that greater maternal
smoking heaviness caused lower offspring birth weight. However, in the maternal ever smoker
group these effects were noticeably stronger. Interestingly, in the maternal never smoker
group the effects of maternal smoking heaviness flipped sign and became weakly positive.
Taken together, these observations support our use of birth weight as a positive control
outcome. In the analyses using the adjusted GWAS, the direction of effect was often consistent
with analyses using the unadjusted GWAS, but the adjusted GWAS had lower statistical power,
resulting in weaker evidence (Figure S3, Figure S4). There was little evidence that paternal
smoking heaviness influenced offspring birth weight (Figure 5, Figure S3; Table S18).

The one-sample MR stratified smoking samples comprised between 8,814 and 9,065
participants in maternal ever smokers, 7,357 and 7,624 in maternal never smokers, 12,004 and
12,339 in paternal ever smokers and 4,445 and 4,623 in paternal never smokers, with numbers
differing across outcomes (Table S11). Whilst the sample size was smaller and thus power was
low, the magnitude of effect became slightly stronger in ever smokers for the effects of
maternal smoking heaviness instrumented by rs16969968 in *CHRNA5* on WHR and maternal
smoking heaviness instrumented by cigarettes per day on BMI (Figure 6A, Table S12). There
was additionally some evidence of an effect of maternal smoking heaviness instrumented by
rs16969968 in *CHRNA5* on DBP and SBP in ever smokers. There was weak evidence of an effect
of maternal smoking heaviness instrumented by rs16969968 in *CHRNA5* on TC and LDL-
cholesterol in never smokers, although this could have been attributable to type 1 error (Figure
6B, Table S12). There was very little evidence of paternal smoking effects on any outcome
(Table S13). As with all stratified analyses, the potential for collider bias should be considered
when interpreting these results.

Discussion.

Employing intergenerational MR analyses across three large cohorts, we found robust evidence supporting a causal effect of greater maternal smoking heaviness (but not initiation) on higher WHR in adult offspring. We also found suggestive evidence that greater maternal smoking heaviness causes greater offspring adult BMI and circulating CRP. We did not find robust evidence of maternal smoking effects on other cardiometabolic risk factors or of paternal smoking effects on any of the outcomes investigated. The MR models in this study cannot distinguish whether the estimated effects reflect maternal or paternal smoking before conception, during pregnancy, or after birth. They are therefore not specific to exposure in pregnancy, and we cannot determine from these results whether the observed effect of maternal smoking on adult offspring WHR is driven by pre-conception, intrauterine or postnatal mechanisms. A purely postnatal explanation appears less likely based on the weaker paternal effects observed, although this should be interpreted with caution, as unmeasured differences in parental caregiving, contact, or social expectations may contribute to stronger mother-offspring effects. Thus, our findings may reflect true effects that are similar across exposure to maternal smoking at different life stages, or alternatively we may have missed effects that are stronger or weaker at different critical or sensitive periods. If the assumptions underpinning our analyses hold, this study is consistent with previous non-genetic epidemiological findings, which identify an association between maternal smoking and higher central adiposity in offspring, that persists into adulthood (13, 14). Although there was some indication of an effect of maternal smoking on BMI and circulating CRP in the two-sample analyses, the BMI effect was weaker than that observed for WHR and did not replicate in the one-sample MR. CRP was not available for one-sample analysis. Overall, this pattern may suggest that any influence of maternal smoking heaviness relates specifically to the fat mass component of BMI.

Several potential mechanisms for the effect of maternal smoking on offspring adiposity have been proposed. In animal studies, maternal nicotine exposure has been associated with alterations in adipose tissue and glucose metabolism (82, 83). Although reduced fetal growth has been suggested as a DOHaD-related mechanism (84, 85), evidence from MR studies provides limited support for broad intrauterine programming effects (57), and such interpretations should therefore be made cautiously. Observational studies also show that

associations between parental smoking and offspring overweight are often independent of

fetal or postnatal growth and birth weight, which further limits support for a fetal growth–

mediated explanation (12). Furthermore, sibling studies have reported that the association

between parental smoking and offspring obesity/overweight in childhood and adulthood

attenuates when assessed within siblings (20, 21). Such attenuation could indicate that familial

confounding is an important driver of these associations, although the sibling estimates

typically have wide confidence intervals which would also be consistent with meaningful causal

effects. It is also difficult to directly compare effect sizes from our MR analyses with those from

previous sibling studies, due to differences in the definition and measurement units of the

smoking exposures and in estimands obtained across methods.

The limited evidence we observed for an effect of paternal smoking on WHR in adult offspring

may be considered in the context of previous maternal and paternal comparison studies (22,

86). Such studies are often interpreted under the assumption that, if an intrauterine effect

exists, the association of maternal smoking with offspring outcomes should be stronger than

the equivalent paternal association (87). Earlier observational investigations and meta-

analyses appeared consistent with this assumption, reporting more adverse maternal relative

to paternal associations of parental smoking with childhood overweight and obesity (22, 86,

88). However, maternal-paternal comparisons are generally more informative for pregnancy

outcomes, which occur during the exposure window itself, than for long-term offspring

outcomes (23), where postnatal environmental and familial influences can accumulate and

obscure intrauterine effects. Consistent with this, a more recent individual participant data

meta-analysis including 229,158 families (24) reported maternal and paternal associations of

comparable magnitude for childhood overweight, indicating that earlier maternal-paternal

differences may have reflected residual confounding rather than true intrauterine effects.

These limitations underscore the value of approaches such as MR in differentiating putative

intrauterine causal effects from shared familial confounding when interrogating long-term

offspring phenotypes.

Single-trait assortative mating, or nonrandom matching between spouses, occurs when

partners are selected on the basis of a single phenotype (89). For instance, if individuals who

smoke are more likely to select partners who also smoke, the resulting enrichment of smoking-

concordant couples could bias associations in our study. In using a WLM to estimate parental

genetic effects, we assume that the same phenotype was measured in the samples of mothers,

fathers, and offspring, and that cross-locus genetic correlations due to assortative mating are

absent. In addition, within a family context, it is difficult to fully unpick the effects of individual

behaviour. Whilst it has been shown that the DNA methylation signature associated with

passive smoke exposure is much less pronounced than that of own smoking, passive smoking

or offspring's own smoking behaviour may still have an impact on findings. Therefore, the

effects that we found may encompass (i) maternal exposure to second-hand smoke from the

partner during pregnancy, due to unmodelled assortative mating effects, (ii) postnatal

exposure to second-hand smoke during the offspring's childhood, and (iii) offspring smoking in

adolescence and early adulthood.

There are several strengths of this study. For the main analysis, we took advantage of novel

statistical methods (28, 60, 90, 91) recently developed to conduct intergenerational two-

sample MR, by estimating the effects of parental genotype on offspring outcomes in

adulthood, adjusting for the offspring's own genotype and (when necessary) the other parent's

genotype. This approach removed the need to analyse a subset of individuals with complete

maternal, paternal, and offspring genotype data available (as we have done for the one-sample

MR analyses). In addition, we applied linear mixed model association methods to data from

large population-based cohorts that comprised related individuals: HUNT, UKB and ALSPAC,

increasing our available sample size considerably. We adjusted for the offspring's and other

parent's genotype, which is crucial to preserve the key exclusion restriction assumption of MR

(92). Importantly, we included birth weight as a positive control outcome, demonstrating that

our method is able to detect the expected causal effect of maternal smoking on offspring birth

weight. In particular, our MR results indicated an effect of both maternal and paternal smoking

initiation on offspring birth weight. However, the presence of a paternal effect raises the

possibility that the smoking initiation instrument may be picking up effects of other exposures

besides smoking, via horizontal pleiotropy. We were also able to stratify MR analyses by

parental smoking status; if parental smoking heaviness exhibits a putative causal effect in

parental never smokers, this indicates our method is biased. We found some evidence that

heavier maternal smoking causes lower offspring birth weight in the unstratified sample, but

these effects were stronger in ever smokers.

An important limitation of this study is that despite relatively large sample sizes, low power was an issue, particularly within some of the stratified sensitivity analyses. These analyses should therefore be interpreted with appropriate caution. Moreover, smoking initiation is an example of a complex behavioural exposure where pleiotropy may be operating (93, 94). Smoking initiation has been shown to associate with risk-taking behaviours, personality traits, and externalising disorders (70, 71). To strengthen this study, we explored several indicators for smoking and conducted multiple sensitivity analyses. The relationship between smoking and body composition is particularly complex (68, 69). Suggestions of a common biological basis for nicotine addiction and obesity have been proposed, with higher adiposity influencing smoking behaviour (69, 95). This link identified between obesity and smoking behaviour may have implications for weight control and smoking prevention strategies (69). We identified several body composition measures which exhibit high genetic correlation with smoking indicators in publicly available GWAS data (52). Our MVMR analyses suggest that smoking initiation may be an unreliable exposure for MR analyses. In addition, a potential source of bias could arise from gene-sex interactions in the two-sample WLM analyses, if residual sex differences in SNP-outcome effects remain even after adjusting for offspring sex. This consideration is particularly relevant for WHR, which has well-established sex-specific genetic architecture (96), and in theory this could contribute to the stronger maternal MR estimate observed for this trait. However, since we observed similar maternal effects on BMI and CRP, which are less sexually dimorphic genetically, this is unlikely to be a major source of bias for our MR analyses. While all our outcome GWAS adjusted for offspring sex, they did not explicitly model gene-sex interactions, so some residual bias cannot be ruled out. Despite this, previously findings suggest that maternal and paternal BMI and glucose traits both exhibit null MR effects on offspring cardiometabolic risk factors in this data set (41, 42). Such bias is therefore unlikely to fully explain these patterns of associations. Finally, our study included only participants of White European ancestry from high income countries, therefore our results may not be generalisable to other populations.

In conclusion, our study provides evidence that heavier maternal smoking causes greater WHR in adult offspring, with more tentative indications of effects on offspring BMI and circulating CRP. We did not find robust evidence for maternal smoking effects on other cardiometabolic risk factors, or for effects of paternal smoking on any of the cardiometabolic factors examined.

Triangulation with complementary study designs will be important for strengthening causal
inference, and our findings, which are compatible with causal effects of maternal smoking on
central adiposity in adult offspring, reinforce the public-health rationale for promoting smoking
cessation prior to pregnancy.

Acknowledgements.

The Trøndelag Health Study (HUNT) is a collaboration between HUNT Research Centre (Faculty

of Medicine and Health Sciences, Norwegian University of Science and Technology NTNU),

Trøndelag County Council, Central Norway Regional Health Authority, and the Norwegian

Institute of Public Health. In addition, we are extremely grateful to all the families who took

part in the ALSPAC study, the midwives for their help in recruiting them, and the whole ALSPAC

team, which includes interviewers, computer and laboratory technicians, clerical workers,

research scientists, volunteers, managers, receptionists, and nurses. We would like to thank

the UK Biobank study and all participants who contributed to it, as well as the authors of the

GWAS who made their summary statistics available for the benefit of this work.

References.

1.   Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of
369 diseases and injuries in 204 countries and territories: a systematic analysis for the Global
Burden of Disease Study 2019. The Lancet. 2020;396(10258):1204-22.
2.   Barker DJP, Hales CN, Fall CHD, Osmond C, Phipps K, Clark PMS. Type 2 (non-insulin-
dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to
reduced fetal growth. Diabetologia. 1993;36(1):62-7.
3.   Langley-Evans SC, McMullen S. Developmental Origins of Adult Disease. Medical
Principles and Practice. 2010;19(2):87-98.
4.   Deodati A, Inzaghi E, Cianfarani S. Epigenetics and In Utero Acquired Predisposition to
Metabolic Disease. Frontiers in Genetics. 2020;10.
5.   Mandy M, Nyirenda M. Developmental Origins of Health and Disease: the relevance
to developing nations. Int Health. 2018;10(2):66-70.
6.   Moen G-H, Brumpton B, Willer C, Åsvold BO, Birkeland KI, Wang G, et al. Mendelian
randomization study of maternal influences on birthweight and future cardiometabolic risk in
the HUNT cohort. Nature Communications. 2020;11(1):5404.
7.   Barker DJP, Osmond C. INFANT MORTALITY, CHILDHOOD NUTRITION, AND ISCHAEMIC
HEART DISEASE IN ENGLAND AND WALES. The Lancet. 1986;327(8489):1077-81.
8.   Barker DJP, Osmond C, Winter PD, Margetts B, Simmonds SJ. WEIGHT IN INFANCY
AND DEATH FROM ISCHAEMIC HEART DISEASE. The Lancet. 1989;334(8663):577-80.
9.   Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life
conditions on adult health and disease. N Engl J Med. 2008;359(1):61-73.
10.   Mund M, Louwen F, Klingelhoefer D, Gerber A. Smoking and pregnancy--a review on
the first major environmental risk factor of the unborn. Int J Environ Res Public Health.
2013;10(12):6485-99.
11.   Banderali G, Martelli A, Landi M, Moretti F, Betti F, Radaelli G, et al. Short and long
term health effects of parental tobacco smoking during pregnancy and lactation: a
descriptive review. Journal of Translational Medicine. 2015;13(1):327.
12.   Oken E, Levitan EB, Gillman MW. Maternal smoking during pregnancy and child
overweight: systematic review and meta-analysis. International Journal of Obesity.
2008;32(2):201-10.
13.   Kataria Y, Gaewsky L, Ellervik C. Prenatal smoking exposure and cardio-metabolic risk
factors in adulthood: a general population study and a meta-analysis. International Journal of
Obesity. 2019;43(4):763-73.
14.   Albers L, Sobotzki C, Kuß O, Ajslev T, Batista RFL, Bettiol H, et al. Maternal smoking
during pregnancy and offspring overweight: is there a dose–response relationship? An
individual patient data meta-analysis. International Journal of Obesity. 2018;42(7):1249-64.
15.   Northstone K, Golding J, Davey Smith G, Miller LL, Pembrey M. Prepubertal start of
father's smoking and increased body fat in his sons: further characterisation of paternal
transgenerational responses. European Journal of Human Genetics. 2014;22(12):1382-6.
16.   Carslake D, Pinger PR, Romundstad P, Davey Smith G. Early-Onset Paternal Smoking
and Offspring Adiposity: Further Investigation of a Potential Intergenerational Effect Using
the HUNT Study. PLoS One. 2016;11(12):e0166952.
17.   Kitaba NT, Knudsen GTM, Johannessen A, Rezwan FI, Malinovschi A, Oudin A, et al.
Fathers' preconception smoking and offspring DNA methylation. Clin Epigenetics.
2023;15(1):131.

18.   Richmond RC, Suderman M, Langdon R, Relton CL, Davey Smith G. DNA methylation
as a marker for prenatal smoke exposure in adults. Int J Epidemiol. 2018;47(4):1120-30.
19.   Yang Q, Millard LAC, Davey Smith G. Proxy gene-by-environment Mendelian
randomization study confirms a causal effect of maternal smoking on offspring birthweight,
but little evidence of long-term influences on offspring health. Int J Epidemiol.
2020;49(4):1207-18.
20.   Iliadou AN, Koupil I, Villamor E, Altman D, Hultman C, Långström N, et al. Familial
factors confound the association between maternal smoking during pregnancy and young
adult offspring overweight. International Journal of Epidemiology. 2010;39(5):1193-202.
21.   Hawkins SS, Baum CF, Rifas-Shiman SL, Oken E, Taveras EM. Examining Associations
between Perinatal and Postnatal Risk Factors for Childhood Obesity Using Sibling
Comparisons. Childhood Obesity. 2019;15(4):254-61.
22.   Riedel C, Schönberger K, Yang S, Koshy G, Chen Y-C, Gopinath B, et al. Parental
smoking and childhood obesity: higher effect estimates for maternal smoking in pregnancy
compared with paternal smoking—a meta-analysis. International Journal of Epidemiology.
2014;43(5):1593-606.
23.   Davey Smith G. Assessing intrauterine influences on offspring health outcomes: can
epidemiological studies yield robust findings? Basic Clin Pharmacol Toxicol. 2008;102(2):245-
56.
24.   Philips EM, Santos S, Trasande L, Aurrekoetxea JJ, Barros H, von Berg A, et al. Changes
in parental smoking during pregnancy and risks of adverse birth outcomes and childhood
overweight in Europe and North America: An individual participant data meta-analysis of
229,000 singleton births. PLOS Medicine. 2020;17(8):e1003182.
25.   Horikoshi M, Beaumont RN, Day FR, Warrington NM, Kooijman MN, Fernandez-Tajes
J, et al. Genome-wide associations for birth weight and correlations with adult disease.
Nature. 2016;538(7624):248-52.
26.   Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology
contribute to understanding environmental determinants of disease? Int J Epidemiol.
2003;32(1):1-22.
27.   Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian
randomization: using genes as instruments for making causal inferences in epidemiology. Stat
Med. 2008;27(8):1133-63.
28.   Evans DM, Moen G-H, Hwang L-D, Lawlor DA, Warrington NM. Elucidating the role of
maternal environmental exposures on offspring health and disease using two-sample
Mendelian randomization. International Journal of Epidemiology. 2019;48(3):861-75.
29.   Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et
al. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian
Randomization: The STROBE-MR Statement. JAMA. 2021;326(16):1614-21.
30.   Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ,
et al. Strengthening the reporting of observational studies in epidemiology using mendelian
randomisation (STROBE-MR): explanation and elaboration. BMJ. 2021;375:n2233.
31.   Åsvold BO, Langhammer A, Rehn TA, Kjelvik G, Grøntvedt TV, Sørgjerd EP, et al.
Cohort Profile Update: The HUNT Study, Norway. International Journal of Epidemiology.
2022;52(1):e80-e91.
32.   Krokstad S, Langhammer A, Hveem K, Holmen TL, Midthjell K, Stene TR, et al. Cohort
Profile: the HUNT Study, Norway. Int J Epidemiol. 2013;42(4):968-77.

33. Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and
surveillance throughout 30 years. Acta Obstet Gynecol Scand. 2000;79(6):435-9.
34. Brumpton BM, Graham S, Surakka I, Skogholt AH, Løset M, Fritsche LG, et al. The
HUNT study: A population-based cohort for genetic research. Cell Genomics.
2022;2(10):100193.
35. Næss M, Kvaløy K, Sørgjerd EP, Sætermo KS, Norøy L, Røstad AH, et al. Data Resource
Profile: The HUNT Biobank. Int J Epidemiol. 2024;53(3).
36. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M. Robust
relationship inference in genome-wide association studies. Bioinformatics. 2010;26(22):2867-
73.
37. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open
access resource for identifying the causes of a wide range of complex diseases of middle and
old age. PLoS Med. 2015;12(3):e1001779.
38. Fraser A, Macdonald-Wallis C, Tilling K, Boyd A, Golding J, Davey Smith G, et al. Cohort
Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. Int J
Epidemiol. 2013;42(1):97-110.
39. Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, et al. Cohort Profile:
the 'children of the 90s'--the index offspring of the Avon Longitudinal Study of Parents and
Children. Int J Epidemiol. 2013;42(1):111-27.
40. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
capture (REDCap)--a metadata-driven methodology and workflow process for providing
translational research informatics support. J Biomed Inform. 2009;42(2):377-81.
41. Bond TA, Bhatta L, Yang Q, Moen G-H, Wang G, Beamont RN, et al. Parental body
mass index and offspring cardiovascular risk factors in adulthood: an intergenerational
Mendelian randomization study. medRxiv. 2025:2025.05.06.25327111.
42. Bhatta L, Bond TA, Warrington NM, Wang G, Denos M, Evans DM, et al. Exploring the
effect of maternal glycemic traits on offspring cardiometabolic risk factors in adulthood: an
intergenerational Mendelian randomization study. medRxiv. 2025:2025.05.07.25326949.
43. Pereira RD, Rietveld CA, van Kippersluis H. The interplay between maternal smoking
and genes in offspring birth weight. Journal of Human Resources. 2022.
44. Tyrrell J, Huikari V, Christie JT, Cavadino A, Bakker R, Brion M-JA, et al. Genetic
variation in the 15q25 nicotinic acetylcholine receptor gene cluster (CHRNA5–CHRNA3–
CHRNB4) interacts with maternal self-reported smoking status during pregnancy to influence
birth weight. Human molecular genetics. 2012;21(24):5344-58.
45. Wang X, Zuckerman B, Pearson C, Kaufman G, Chen C, Wang G, et al. Maternal
cigarette smoking, metabolic gene polymorphism, and infant birth weight. Jama.
2002;287(2):195-202.
46. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank
resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203-9.
47. McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. A
reference panel of 64,976 haplotypes for genotype imputation. Nature Genetics.
2016;48(10):1279-83.
48. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al. An
integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56-
65.

49.   Lassi G, Taylor AE, Timpson NJ, Kenny PJ, Mather RJ, Eisen T, et al. The CHRNA5-A3-B4
Gene Cluster and Smoking: From Discovery to Therapeutics. Trends Neurosci.
2016;39(12):851-61.
50.   Wang JC, Cruchaga C, Saccone NL, Bertelsen S, Liu P, Budde JP, et al. Risk for nicotine
dependence and lung cancer is conferred by mRNA expression levels and amino acid change
in CHRNA5. Human Molecular Genetics. 2009;18(16):3125-35.
51.   Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, et al. Association studies of up to 1.2
million individuals yield new insights into the genetic etiology of tobacco and alcohol use. Nat
Genet. 2019;51(2):237-44.
52.   Saunders GRB, Wang X, Chen F, Jang S-K, Liu M, Wang C, et al. Genetic diversity fuels
gene discovery for tobacco and alcohol use. Nature. 2022;612(7941):720-4.
53.   Millard LAC, Munafò MR, Tilling K, Wootton RE, Davey Smith G. MR-pheWAS with
stratification and interaction: Searching for the causal effects of smoking heaviness identified
an effect on facial aging. PLOS Genetics. 2019;15(10):e1008353.
54.   Richmond RC, Davey Smith G. Mendelian Randomization: Concepts and Scope. Cold
Spring Harb Perspect Med. 2022;12(1).
55.   Warrington NM, Beaumont RN, Horikoshi M, Day FR, Helgeland Ø, Laurin C, et al.
Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic
risk factors. Nature Genetics. 2019;51(5):804-14.
56.   Warrington NM, Freathy RM, Neale MC, Evans DM. Using structural equation
modelling to jointly estimate maternal and fetal effects on birthweight in the UK Biobank. Int
J Epidemiol. 2018;47(4):1229-41.
57.   Bond TA, Richmond RC, Karhunen V, Cuellar-Partida G, Borges MC, Zuber V, et al.
Exploring the causal effect of maternal pregnancy adiposity on offspring adiposity: Mendelian
randomisation using polygenic risk scores. BMC Medicine. 2022;20(1):34.
58.   Wu Y, Zhong X, Lin Y, Zhao Z, Chen J, Zheng B, et al. Estimating genetic nurture with
summary statistics of multigenerational genome-wide association studies. Proc Natl Acad Sci
U S A. 2021;118(25).
59.   Beaumont RN, Flatley C, Vaudel M, Wu X, Chen J, Moen GH, et al. Genome-wide
association study of placental weight identifies distinct and shared genetic influences
between placental and fetal growth. Nat Genet. 2023;55(11):1807-19.
60.   Warrington NM, Hwang L-D, Nivard MG, Evans DM. Estimating direct and indirect
genetic effects on offspring phenotypes using genome-wide summary results data. Nature
Communications. 2021;12(1):5420.
61.   Jiang L, Zheng Z, Qi T, Kemper KE, Wray NR, Visscher PM, et al. A resource-efficient
tool for mixed model association analysis of large-scale data. Nat Genet. 2019;51(12):1749-
55.
62.   Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide
association scans. Bioinformatics. 2010;26(17):2190-1.
63.   Burgess S, & Thompson, S.G. Mendelian Randomization: Methods for Causal
Inference Using Genetic Variants. 2nd edition ed: Chapman and Hall/CRC. ; 2021.
64.   Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol.
2015;44(2):512-25.
65.   Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian
Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet
Epidemiol. 2016;40(4):304-14.

66.   Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian
randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46(6):1985-
98.
67.   Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using
the MR-Egger method. Eur J Epidemiol. 2017;32(5):377-89.
68.   Taylor AE, Morris RW, Fluharty ME, Bjorngaard JH, Åsvold BO, Gabrielsen ME, et al.
Stratification by Smoking Status Reveals an Association of CHRNA5-A3-B4 Genotype with
Body Mass Index in Never Smokers. PLOS Genetics. 2014;10(12):e1004799.
69.   Carreras-Torres R, Johansson M, Haycock PC, Relton CL, Davey Smith G, Brennan P, et
al. Role of obesity in smoking behaviour: Mendelian randomisation study in UK Biobank. Bmj.
2018;361:k1767.
70.   Khouja JN, Wootton RE, Taylor AE, Davey Smith G, Munafò MR. Association of genetic
liability to smoking initiation with e-cigarette use in young adults: A cohort study. PLoS Med.
2021;18(3):e1003555.
71.   Schellhas L, Haan E, Easey KE, Wootton RE, Sallis HM, Sharp GC, et al. Maternal and
child genetic liability for smoking and caffeine consumption and child mental health: an
intergenerational genetic risk score analysis in the ALSPAC cohort. Addiction.
2021;116(11):3153-66.
72.   Sanderson E, Richardson TG, Morris TT, Tilling K, Davey Smith G. Estimation of causal
effects of a time-varying exposure at multiple time points through multivariable mendelian
randomization. PLoS Genet. 2022;18(7):e1010290.
73.   Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of
pleiotropic genetic variants to estimate causal effects. Am J Epidemiol. 2015;181(4):251-60.
74.   Armstrong RA. When to use the Bonferroni correction. Ophthalmic Physiol Opt.
2014;34(5):502-8.
75.   Brito Nunes C, Huang P, Wang G, Lundberg M, D'Urso S, Wootton RE, et al. Mendelian
randomization study of maternal coffee consumption and its influence on birthweight,
stillbirth, miscarriage, gestational age and pre-term birth. Int J Epidemiol. 2023;52(1):165-77.
76.   Wang G, Bhatta L, Moen GH, Hwang LD, Kemp JP, Bond TA, et al. Investigating a
Potential Causal Relationship Between Maternal Blood Pressure During Pregnancy and Future
Offspring Cardiometabolic Health. Hypertension. 2022;79(1):170-7.
77.   Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex
trait analysis. Am J Hum Genet. 2011;88(1):76-82.
78.   Support ST. StataCorp. 2019. Stata Statistical Software: Release 16. College Station,
TX: StataCorp LLC. 2019 [
79.   Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, et al. LD Score
regression distinguishes confounding from polygenicity in genome-wide association studies.
Nat Genet. 2015;47(3):291-5.
80.   Bond TB, L; Yang, Q; Moen, Gunn-H; Wang, G; Beaumont, RN; Morris, T; Hwang, L-D;
Wootton, RE; Corfield, EC; Warrington, NM; Magnus, MC; Havdhal, A; Borges, MC; Lawlor,
DA; Åsvold, B-O; Brumpton, BM; Evans, DM. Parental body mass index and offspring
cardiovascular risk factors in adulthood: an intergenerational Mendelian randomization
study. In preparation. 2024.
81.   L B, TA B, NM W, G W, DM E, Lawlor D, et al. Leveraging parental genotypes to
understand the effect of maternal glycemia on offspring cardiometabolic factors in
adulthood: an intergenerational Genome-Wide Association and Mendelian randomization
Study. In preparation. 2024.

82.   Gao YJ, Holloway AC, Su LY, Takemori K, Lu C, Lee RM. Effects of fetal and neonatal
exposure to nicotine on blood pressure and perivascular adipose tissue function in adult life.
Eur J Pharmacol. 2008;590(1-3):264-8.

83.   Somm E, Schwitzgebel VM, Vauthay DM, Aubert ML, Hüppi PS. Prenatal nicotine
exposure and the programming of metabolic and cardiovascular disorders. Mol Cell
Endocrinol. 2009;304(1-2):69-77.

84.   Parsons TJ, Power C, Manor O. Fetal and early life growth and body mass index from
birth to early adulthood in 1958 British cohort: longitudinal study. Bmj.
2001;323(7325):1331-5.

85.   Simmons R. Perinatal programming of obesity. Semin Perinatol. 2008;32(5):371-4.

86.   Howe LD, Matijasevich A, Tilling K, Brion M-J, Leary SD, Smith GD, et al. Maternal
smoking during pregnancy and offspring trajectories of height and adiposity: comparing
maternal and paternal associations. International Journal of Epidemiology. 2012;41(3):722-
32.

87.   Brumpton B, Sanderson E, Heilbron K, Hartwig FP, Harrison S, Vie GÅ, et al. Avoiding
dynastic, assortative mating, and population stratification biases in Mendelian randomization
through within-family analyses. Nature Communications. 2020;11(1):3519.

88.   da Silva Magalhães EI, Peixoto Lima N, Baptista Menezes AM, Gonçalves H,
Wehrmeister FC, Formoso Assunção M, et al. Maternal smoking during pregnancy and
offspring body composition in adulthood: Results from two birth cohort studies. BMJ Open.
2019;9(6):e023852.

89.   Hartwig FP, Davies NM, Davey Smith G. Bias in Mendelian randomization due to
assortative mating. Genet Epidemiol. 2018;42(7):608-20.

90.   Wu Y, Zhong X, Lin Y, Zhao Z, Chen J, Zheng B, et al. Estimating genetic nurture with
summary statistics of multigenerational genome-wide association studies. Proceedings of the
National Academy of Sciences. 2021;118(25):e2023184118.

91.   Beaumont RN, Flatley C, Vaudel M, Wu X, Chen J, Moen G-H, et al. Genome-wide
association study of placental weight in 179,025 children and parents reveals distinct and
shared genetic influences between placental and fetal growth. medRxiv.
2022:2022.11.25.22282723.

92.   Lawlor D, Richmond R, Warrington N, McMahon G, Davey Smith G, Bowden J, et al.
Using Mendelian randomization to determine causal effects of maternal pregnancy
(intrauterine) exposures on offspring outcomes: Sources of bias and methods for assessing
them. Wellcome Open Res. 2017;2:11.

93.   Reed ZE, Wootton RE, Khouja JN, Richardson TG, Sanderson E, Davey Smith G, et al.
Exploring pleiotropy in Mendelian randomisation analyses: What are genetic variants
associated with "cigarette smoking initiation" really capturing? medRxiv.
2023:2023.08.04.23293638.

94.   Gage SH, Sallis HM, Lassi G, Wootton RE, Mokrysz C, Davey Smith G, et al. Does
smoking cause lower educational attainment and general cognitive ability? Triangulation of
causal evidence using multiple study designs. Psychol Med. 2022;52(8):1578-86.

95.   Thorgeirsson TE, Gudbjartsson DF, Sulem P, Besenbacher S, Styrkarsdottir U,
Thorleifsson G, et al. A common biological basis of obesity and nicotine addiction. Transl
Psychiatry. 2013;3(10):e308.

96.   Winkler TW, Justice AE, Graff M, Barata L, Feitosa MF, Chu S, et al. The Influence of
Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-
Wide Interaction Study. PLoS Genet. 2015;11(10):e1005378.

Sources of funding.

The genotyping in HUNT was financed by the National Institutes of Health (NIH); University of Michigan; The Research Council of Norway; The Liaison Committee for Education, Research and Innovation in Central Norway; and the Joint Research Committee between St. Olavs hospital and the Faculty of Medicine and Health Sciences, NTNU. This work was in part supported by the Integrative Epidemiology Unit which receives funding from the UK Medical Research Council and the University of Bristol (MC_UU_00032/01 and MC_UU_00032/05). The UK Medical Research Council and Wellcome (Grant ref: MR/Z505924/1) and the University of Bristol provide core support for ALSPAC. Genotyping of the ALSPAC maternal samples was funded by the Wellcome Trust (WT088806) and the offspring samples were genotyped by Sample Logistics and Genotyping Facilities at the Wellcome Trust Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf); this research was specifically funded by Wellcome Trust and MRC (076467/Z/05/Z, 102215/2/13/2) and British Heart Foundation (BHF) (CS/15/6/31468). This publication is the work of the authors and will serve as guarantors for the contents of this paper. GDS conducts research at the NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. GMP was supported by the GW4 Biomed Doctoral Training Programme, awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/UKRI (MR/N0137941/1) whilst completing this work. GW and NMW are supported by a National Health and Medical Research Council (NHMRC; Australia) Emerging Leadership Fellowship (APP2008723). DME is funded by an Australian National Health and Medical Research Council Investigator Grant (APP2017942). GHM is the recipient of an Australian Research Council Discovery Early Career Award (Project number: DE220101226) funded by the Australian Government and supported by the Research Council of Norway (Project grant: 325640 & Mobility grant: 287198). DAL's contribution is supported by the British Heart Foundation (CH/F/20/90003 & AA/18/1/34219) and European Research Council (grant No. 101021566). DAL's contribution to this work is supported by the European Research

council (101021566) and BHF (CH/F/20/90003 and AA/18/1/34219), and TAB's work was

supported by the BHF (AA/18/1/34219). LB, BOA, and BMB work in a research unit funded by

the Liaison Committee for education, research and innovation in Central Norway and the Joint

Research Committee between St. Olavs Hospital and the Faculty of Medicine and Health

Sciences, NTNU.

Data and code sharing.

Data access for the Avon Longitudinal Study of Parents and Children (ALSPAC) operates via a

managed open access system. Approved proposals are reviewed by the ALSPAC Executive

Committee. Full details are provided in the ALSPAC Data Management Plan

(www.bristol.ac.uk/alspac/researchers/data-access/documents/alspac-data-management-

plan.pdf). To request access to data from the Trøndelag Health Study (HUNT), researchers

affiliated with Norwegian research institutes can apply for the use of HUNT data and biological

samples, subject to approval by the Regional Committee for Medical and Health Research

Ethics. Researchers from other countries may also apply if collaborating with a Norwegian

Principal Investigator. All applications are reviewed by the HUNT Data Access Committee, and

successful applicants are required to enter into data access and/or material transfer

agreements. Detailed information on the application process, ethical requirements, and

available datasets can be found on the HUNT website (www.ntnu.edu/hunt/data). Access to

UK Biobank (UKB) data is obtained through a standard application process. Researchers

register with UKB, submit a study proposal, and obtain approval from the UKB Access

Management Team. Approved applicants receive access to de-identified data under UKB's

terms of use. Further information is available on the UK Biobank website

(www.ukbiobank.ac.uk/enable-your-research/apply-for-access).

Upon publication, analysis code used in this study will be made publicly available via GitHub

repository.

None of the material has been published or is under consideration for publication elsewhere.

Competing interests.

All authors declare no competing interests.

FIGURES.

Figure 1.   Study design overview and flowchart for instruments used in two-sample MR
(GWAS).

Figure 2. Directed acyclic graphs indicating two scenarios to explain the causal effect of
parental smoking on offspring cardiometabolic risk factors in adulthood. A. Intergenerational
MR estimating maternal smoking on offspring cardiometabolic risk factors in adulthood. The
offspring and paternal SNP are adjusted for, and thus dotted paths are blocked B.
Intergenerational MR estimating paternal smoking on offspring cardiometabolic risk factors in
adulthood. The offspring and maternal SNP are adjusted for, and thus dotted paths are
blocked.

Figure 3. Two-sample MR for maternal and paternal smoking heaviness and initiation onto 11
long term cardiometabolic outcomes in offspring. A. Maternal smoking on offspring
cardiometabolic risk factors in adulthood. B. Paternal smoking on offspring cardiometabolic
risk factors in adulthood. MR estimates for the effect of smoking heaviness can be interpreted
as the average change in the outcome, in standard deviation (SD) units, per one SD greater
parental cigarettes smoked per day. MR estimates for the effect of smoking initiation can be
interpreted as the average change in the outcome, in SD units, per doubling in the odds of
smoking initiation.

Figure 4. One-sample MR for smoking heaviness onto 9 long term cardiometabolic outcomes
in offspring. A. Maternal smoking on offspring cardiometabolic risk factors in adulthood. B.
Paternal smoking on offspring cardiometabolic risk factors in adulthood. Estimates represent
the average change in offspring cardiometabolic outcomes per additional effect allele in the
unweighted smoking GRS and per copy of the CHRNA5 risk allele, expressed in standard
deviation (SD) units of each outcome. These estimates reflect associations between the
parental genetic instruments and offspring outcomes, rather than causal effects per unit
change in smoking heaviness.

Figure 5. Two-sample MR for maternal and paternal smoking heaviness and initiation onto
birthweight in offspring, stratified by parental smoking status, using unadjusted (marginal)
genetic effects. A. Maternal smoking exposures on birthweight. B. Paternal smoking exposures
on birthweight. MR estimates for the effect of smoking heaviness can be interpreted as the

average change in the outcome, in standard deviation (SD) units, per one SD greater parental

cigarettes smoked per day. MR estimates for the effect of smoking initiation can be interpreted

as the average change in the outcome, in SD units, per doubling in the odds of smoking

initiation.

Figure 6. One-sample MR for maternal smoking heaviness onto 9 long term cardiometabolic

outcomes in offspring in maternal ever and never smokers. A. Maternal smoking on offspring

cardiometabolic risk factors in adulthood in maternal ever smoking group. B. Maternal smoking

on offspring cardiometabolic risk factors in adulthood in maternal never smokers. Estimates

represent the average change in offspring cardiometabolic outcomes per additional effect

allele in the unweighted smoking GRS and per copy of the CHRNA5 risk allele, expressed in

standard deviation (SD) units of each outcome. These estimates reflect associations between

the parental genetic instruments and offspring outcomes, rather than causal effects per unit

change in smoking heaviness.

TABLES.

Table 1. Descriptive statistics of the offspring's cardiometabolic traits for mother-father-

offspring trios in HUNT, UKB and ALSPAC.

Figure 1. Study design overview and flowchart for instruments used in two-sample MR (GWAS) (Figure adapted from Bond, T and Bhatta, L 2025 (41, 42)).

BMI: body mass index, BW: birth weight, HUNT: Trøndelag Health Study, UKB: UK Biobank, ALSPAC: Avon Longitudinal Study of Parents and Children, EGG: Early Growth Genetics Consortium, GIANT: Genetic Investigation of Anthropometric Traits Consortium, GWAS: genome-wide association study, QC: quality control, MAF: minor allele frequency. BW: birth weight, HUNT: Trøndelag Health Study, UKB: UK Biobank, ALSPAC: Avon Longitudinal Study of Parents and Children, EGG: Early Growth Genetics Consortium, GIANT: Genetic Investigation of Anthropometric Traits Consortium, GWAS: genome wide association study, QC: quality control, MAF: minor allele frequency. a: total number of participants in the HUNT2 and HUNT3 study waves, b: total number of fetuses included in ALSPAC (including participants recruited after 7 years of age), c: only unrelated individuals within the parent and offspring generations were included in the designated samples, d: sample sizes were similar for the other adult outcomes, e: ALSPAC data were included in EGG, f: in HUNT, the parent-offspring samples included siblings in the offspring generation, and for the birth weight analyses parent-offspring pairs were identified via a birth registry instead of via genetic data, resulting in larger samples for parental GWAS and a smaller sample for offspring GWAS compared with adult outcomes, g: we used publicly available

975   summary statistics from the meta-analysis of EGG, UKB and deCODE carried out by Juliusdottir *et al*. (30), h: prior to meta-analysis, A/T and C/G SNPs were
976   removed when comparison of their allele frequency to the HRC or 1000 Genome Project reference panel suggested harmonisation errors.

Figure 2. Directed acyclic graphs indicating two scenarios to explain the causal effect of parental smoking on offspring cardiometabolic risk factors in adulthood. A. Intergenerational MR estimating maternal smoking on offspring cardiometabolic risk factors in adulthood. The offspring and paternal SNP are adjusted for and thus dotted paths are blocked B. Intergenerational MR estimating paternal smoking on offspring cardiometabolic risk factors in adulthood. The offspring and maternal SNP are adjusted for and thus dotted paths are blocked.

A.

BMI
	0.11 (-0.18, 0.41)
	0.26 (0.07, 0.45)
	0.16 (-0.01, 0.34)
	-0.10 (-0.27, 0.07)
	-0.03 (-0.15, 0.09)

WHR
	0.30 (0.05, 0.55)
	0.27 (0.11, 0.42)
	0.21 (0.06, 0.35)
	0.01 (-0.12, 0.14)
	0.01 (-0.08, 0.11)

SBP
	0.07 (-0.14, 0.28)
	-0.03 (-0.19, 0.13)
	0.02 (-0.12, 0.15)
	0.03 (-0.10, 0.15)
	0.00 (-0.08, 0.09)

DBP
	0.00 (-0.25, 0.26)
	-0.04 (-0.21, 0.13)
	-0.03 (-0.18, 0.13)
	-0.02 (-0.16, 0.12)
	-0.07 (-0.17, 0.02)

Glucose
	0.08 (-0.19, 0.35)
	-0.07 (-0.24, 0.11)
	-0.05 (-0.21, 0.12)
	0.03 (-0.12, 0.19)
	-0.08 (-0.18, 0.02)

HbA1c
	-0.15 (-0.48, 0.19)
	-0.05 (-0.26, 0.17)
	-0.02 (-0.22, 0.17)
	-0.07 (-0.24, 0.10)
	-0.11 (-0.23, 0.01)

TC
	0.17 (-0.10, 0.44)
	0.14 (-0.04, 0.31)
	0.05 (-0.11, 0.21)
	0.14 (0.00, 0.28)
	0.11 (0.01, 0.21)

HDL-C
	-0.01 (-0.29, 0.26)
	0.00 (-0.19, 0.20)
	0.07 (-0.10, 0.25)
	0.06 (-0.08, 0.21)
	0.02 (-0.09, 0.13)

LDL-C
	0.13 (-0.16, 0.43)
	0.08 (-0.11, 0.27)
	-0.07 (-0.24, 0.10)
	0.07 (-0.08, 0.23)
	0.08 (-0.02, 0.19)

TG
	0.16 (-0.09, 0.40)
	0.11 (-0.05, 0.27)
	0.13 (-0.02, 0.28)
	0.05 (-0.22, 0.17)
	0.01 (-0.08, 0.11)

log CRP
	0.24 (-0.06, 0.54)
	0.22 (0.01, 0.44)
	0.19 (-0.02, 0.39)
	0.00 (-0.16, 0.16)
	-0.07 (-0.18, 0.04)

Maternal smoking effects

B.

BMI
	0.02 (-0.31, 0.36)
	0.08 (-0.18, 0.34)
	0.07 (-0.15, 0.28)
	-0.15 (-0.35, 0.05)
	-0.08 (-0.22, 0.05)

WHR
	0.08 (-0.19, 0.36)
	0.04 (-0.16, 0.25)
	0.03 (-0.16, 0.21)
	0.00 (-0.17, 0.16)
	-0.01 (-0.12, 0.10)

SBP
	-0.03 (-0.27, 0.22)
	-0.11 (-0.28, 0.05)
	-0.12 (-0.27, 0.03)
	0.05 (-0.09, 0.18)
	0.01 (-0.08, 0.10)

DBP
	0.01 (-0.29, 0.30)
	-0.15 (-0.34, 0.05)
	-0.16 (-0.34, 0.02)
	0.00 (-0.17, 0.17)
	-0.06 (-0.17, 0.05)

Glucose
	-0.13 (-0.44, 0.19)
	0.02 (-0.22, 0.26)
	0.03 (-0.15, 0.22)
	-0.03 (-0.21, 0.15)
	-0.05 (-0.17, 0.07)

HbA1c
	-0.40 (-0.78, -0.03)
	-0.16 (-0.41, 0.08)
	-0.10 (-0.32, 0.12)
	-0.18 (-0.37, 0.02)
	-0.12 (-0.26, 0.02)

TC
	-0.05 (-0.36, 0.26)
	0.07 (-0.13, 0.27)
	0.01 (-0.17, 0.20)
	0.06 (-0.11, 0.22)
	0.14 (0.02, 0.25)

HDL-C
	-0.11 (-0.41, 0.20)
	-0.04 (-0.25, 0.17)
	0.08 (-0.12, 0.28)
	0.17 (0.00, 0.34)
	0.07 (-0.05, 0.19)

LDL-C
	-0.09 (-0.42, 0.25)
	-0.01 (-0.22, 0.21)
	-0.14 (-0.34, 0.06)
	-0.01 (-0.18, 0.17)
	0.13 (0.00, 0.25)

TG
	0.12 (-0.18, 0.42)
	0.12 (-0.08, 0.32)
	0.18 (-0.01, 0.37)
	-0.05 (-0.22, 0.12)
	0.01 (-0.10, 0.12)

log CRP
	-0.02 (-0.36, 0.32)
	-0.04 (-0.34, 0.25)
	-0.05 (-0.28, 0.17)
	-0.06 (-0.24, 0.12)
	-0.10 (-0.23, 0.03)

Paternal smoking effects

SD change in outcome per 1SD greater parental cigarettes smoked per day or per doubling in the odds of parental smoking initiation

Smoking exposure variables

- Smoking heaviness (rs16969968 in CHRNA5)
- Smoking heaviness (Cigarettes per day (2019))
- Smoking heaviness (Cigarettes per day (2022))
- Smoking initiation (2019)
- Smoking initiation (2022)

Figure 3. Two-sample MR for maternal and paternal smoking heaviness and initiation onto 11
long term cardiometabolic outcomes in offspring. Parental genotype was adjusted for offspring
genotype (duos WLM). A. Maternal smoking on offspring cardiometabolic risk factors in
adulthood. B. Paternal smoking on offspring cardiometabolic risk factors in adulthood. MR
estimates for the effect of smoking heaviness can be interpreted as the average change in the
outcome, in standard deviation (SD) units, per one SD greater parental cigarettes smoked per
day. MR estimates for the effect of smoking initiation can be interpreted as the average change
in the outcome, in SD units, per doubling in the odds of smoking initiation.

A. **B.**

Figure 4. One-sample MR for smoking heaviness onto 9 long term cardiometabolic outcomes
in offspring. A. Maternal smoking on offspring cardiometabolic risk factors in adulthood. B.
Paternal smoking on offspring cardiometabolic risk factors in adulthood. Estimates represent
the average change in offspring cardiometabolic outcomes per additional effect allele in the
unweighted smoking GRS and per copy of the CHRNA5 risk allele, expressed in standard
deviation (SD) units of each outcome. These estimates reflect associations between the
parental genetic instruments and offspring outcomes, rather than causal effects per unit
change in smoking heaviness.

A.

B.

SD change in outcome per 1SD greater parental cigarettes smoked per day or per doubling in the odds of parental smoking initiation

Smoking exposure variables

- Smoking heaviness (rs16969968 in CHRNA5)
- Smoking heaviness (Cigarettes per day (2019))
- Smoking heaviness (Cigarettes per day (2022))
- Smoking initiation (2019)
- Smoking initiation (2022)

Figure 5. Two-sample MR for maternal and paternal smoking heaviness and initiation onto birthweight in offspring, stratified by parental smoking status, using unadjusted (marginal) genetic effects. A. Maternal smoking exposures on birthweight. B. Paternal smoking exposures on birthweight. MR estimates for the effect of smoking heaviness can be interpreted as the average change in the outcome, in standard deviation (SD) units, per one SD greater parental cigarettes smoked per day. MR estimates for the effect of smoking initiation can be interpreted as the average change in the outcome, in SD units, per doubling in the odds of smoking initiation.

1019

beta (95% Confidence Interval)

Smoking exposure variables

- Smoking heaviness (rs16969968 in CHRNA5)
- Smoking heaviness (cigarettes per day 2019)
- Smoking heaviness (cigarettes per day 2022)

1022

Figure 6. One-sample MR for maternal smoking heaviness onto 9 long term cardiometabolic
outcomes in offspring in maternal ever and never smokers. A. Maternal smoking on offspring
cardiometabolic risk factors in adulthood in maternal ever smoking group. B. Maternal smoking
on offspring cardiometabolic risk factors in adulthood in maternal never smokers. Estimates
represent the average change in offspring cardiometabolic outcomes per additional effect
allele in the unweighted smoking GRS and per copy of the CHRNA5 risk allele, expressed in
standard deviation (SD) units of each outcome. These estimates reflect associations between
the parental genetic instruments and offspring outcomes, rather than causal effects per unit
change in smoking heaviness.

1032

Table 1. Descriptive statistics of the offspring's cardiometabolic traits for mother-father-offspring trios in HUNT, UKB and ALSPAC.

Offspring Trait (Unit)	HUNT Mother-father-offspring trios			UKB Mother-father-offspring trios			ALSPAC Mother-father-offspring trios		
	N	Mean (SD)	Median (Min-Max)	N	Mean (SD)	Median (Min-Max)	N	Mean (SD)	Median (Min-Max)
BMI (kg/m^2)	15731	26.30 (4.36)	25.7 (15.8-50.3)	993	26.44 (4.65)	25.90 (17.58-46.75)	749	24.43 (4.40)	23.50 (16.27-44.59)
WHR	15634	0.87 (0.08)	0.87 (0.58-1.31)	997	0.84 (0.09)	0.84 (0.59-1.08)	748	0.80 (0.07)	0.80 (0.65-1.04)
SBP (mmHg)	15721	125.90 (15.69)	124.00 (70.00-218.00)	997	127.34 (15.05)	125.50 (91.50-183.00)	756	116.92 (12.23)	116.33 (88.67-164.67)
DBP (mmHg)	15721	72.17 (11.27)	71.00 (38.00-126.00)	997	79.93 (10.46)	79.00 (52.00-118.50)	756	66.62 (7.98)	66.00 (42.33-95.00)
Glucose (mmol/L)	15427	5.18 (0.94)	5.00 (2.30-12.60)	866	4.82 (0.65)	4.79 (2.84-10.33)	649	5.27 (0.48)	5.23 (4.03-6.85)
TC (mmol/L)	15481	5.17 (1.05)	5.10 (2.10-10.90)	955	5.44 (1.01)	5.36 (3.22-8.70)	650	4.42 (0.83)	4.32 (2.02-7.33)
HDL-C (mmol/L)	15474	1.32 (0.33)	1.30 (0.50-2.80)	866	1.39 (0.33)	1.36 (0.65-3.16)	650	1.58 (0.43)	1.53 (0.45-3.18)
LDL-C (mmol/L)	15459	3.54 (0.98)	3.44 (0.76-9.38)	955	3.41 (0.80)	3.31 (1.42-6.02)	649	2.40 (0.77)	2.34 (0.15-5.75)
TG (mmol/L)	15702	1.52 (0.99)	1.28 (0.18-11.73)	950	1.58 (1.03)	1.28 (0.39-6.13)	643	0.95 (0.44)	0.82 (0.27-3.41)
CRP[†] (mg/L)	NA	NA	NA	948	1.82 (2.45)	0.99 (0.09-21.81)	607	1.68 (2.66)	0.72 (0.10-27.69)
HbA1c (mmol/mol)	NA	NA	NA	960	33.36 (3.97)	33.30 (18.10-58.20)	NA	NA	NA

† Traits have been natural log-transformed in one-sample GRS analyses but descriptive statistics presented in the table are on the original scales; DBP: Diastolic blood pressure; SBP: Systolic blood pressure; BMI: Body mass index; TC: Total cholesterol; LDL-C: Low-density lipoprotein cholesterol; HDL-C High-density lipoprotein cholesterol; TG: Triglycerides; HbA1c: Glycated haemoglobin; CRP: C-reactive protein; WHR: Waist-hip-ratio; N: number of offspring with the trait measured; SD: standard deviation; Min: minimum measurement; Max: maximum measurement.